Comments
Zydus Cadila has received final approval from the US health regulator to market Azithromycin for Oral Suspension USP, used to treat bacterial infections, in the American market.
According to a company statement, the medication is used to treat respiratory infections, skin infections, ear infections and sexually transmitted diseases. The drug will be manufactured at the group’s formulations manufacturing facility at Baddi.
The Ahmedabad-based group now has 213 approvals from USFDA. Shares of Cadila Healthcare, the flagship of the Zydus Cadila Group, were trading down 1.59 per cent at Rs 375.30 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.